D3572
Dipeptidyl Peptidase IV Inhibitor IV
Synonym(s):
(S)-1-(4-Methyl-1-(2-pyrimidinyl)-4-piperidylamino)acetyl-2-pyrrolidinecarbonitrile, K579
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Empirical Formula (Hill Notation):
C17H24N6O
Molecular Weight:
328.41
UNSPSC Code:
12352202
NACRES:
NA.77
Recommended Products
General description
Dipeptidyl Peptidase IV Inhibitor IV, also known as K579 ((S)-1-[4-methyl-1-(2-pyrimidinyl)-4-piperidylamino]acetyl-2-pyrrolidinecarbonitrile), is orally available. It has a formula weight of 339.39 g/mol.[1]
Biochem/physiol Actions
Dipeptidyl peptidase IV (DPP IV) is a key enzyme involved in the regulation of incretin hormone levels in the gastrointestinal tract. Incretin hormones, such as glucagon like peptide (GLP-1) and glucose-dependent insulinotropic hormone (GIP) / gastric inhibitory peptide, cause the glucose stimulated release of insulin.[2][3] This allows the endocrine system to preemptively stimulate release insulin in response to ingestion of high sugar foods. Type 2 diabetics demonstrate a greatly reduced incretin induced insulin release response.[4]
This response in hyperglycemic conditions is counterbalanced by the rapid rate of degradation of these incretin hormones by dipeptidyl peptidase IV in normal conditions. Inhibition of dipeptidyl peptidase IV results in longer lifetime of the incretin hormones in the GI tract and thus prolonged stimulation of insulin production. Specific dipeptidyl peptidase inhibitors are actively being explored as drug targets for treating type 2 diabetes and several candidates are actively in clinical trial.[2]
This response in hyperglycemic conditions is counterbalanced by the rapid rate of degradation of these incretin hormones by dipeptidyl peptidase IV in normal conditions. Inhibition of dipeptidyl peptidase IV results in longer lifetime of the incretin hormones in the GI tract and thus prolonged stimulation of insulin production. Specific dipeptidyl peptidase inhibitors are actively being explored as drug targets for treating type 2 diabetes and several candidates are actively in clinical trial.[2]
Storage Class
11 - Combustible Solids
wgk_germany
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Customers Also Viewed
Involvement of the active metabolites in the inhibitory activity of K579 on rat plasma dipeptidyl peptidase IV.
Takasaki K, et al.
European Journal of Pharmacology, 505(1-3), 237-241 (2004)
A Desk Reference on Enzyme Inhibitors, Receptor Antagonists, Drugs, Toxins, Poisons, Biologics, and Therapeutic Leads.
Purich D.
The Inhibitor Index (2017)
Involvement of the active metabolites in the inhibitory activity of K579 on rat plasma dipeptidyl peptidase IV.
Takasaki K, et al.
European Journal of Pharmacology, 505(1-3), 237-241 (2004)
Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes.
Holst J J, et al.
Diabetes Care, 34(2), S251-S257 (2011)
Dipeptidyl peptidase IV (DPP IV) inhibitors: a newly emerging drug class for the treatment of type 2 diabetes.
Green BD, et al.
Diabetes & Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease, 3(3), 159-165 (2006)
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service
